ASX - By Stock
|
PER |
Re:
Ann: ATL1102 Shows Preclinical Activity in Autoimmune Epilepsy
|
|
kosenar
|
47 |
14K |
1 |
09/09/24 |
09/09/24 |
ASX - By Stock
|
47
|
14K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Ann: ATL1102 Shows Preclinical Activity in Autoimmune Epilepsy
|
|
kosenar
|
47 |
14K |
6 |
09/09/24 |
09/09/24 |
ASX - By Stock
|
47
|
14K
|
6
|
|
ASX - By Stock
|
CTO |
Re:
Ann: Quarterly Activities Report and Appendix 5B
|
|
kosenar
|
40 |
9.1K |
3 |
09/09/24 |
09/09/24 |
ASX - By Stock
|
40
|
9.1K
|
3
|
|
ASX - By Stock
|
CTO |
Re:
Ann: Quarterly Activities Report and Appendix 5B
|
|
kosenar
|
40 |
9.1K |
4 |
21/08/24 |
21/08/24 |
ASX - By Stock
|
40
|
9.1K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: Phase IIb study of ATL1102 in DMD completes recruitment
|
|
kosenar
|
238 |
69K |
3 |
22/07/24 |
22/07/24 |
ASX - By Stock
|
238
|
69K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Assumptions
|
|
kosenar
|
35 |
10K |
8 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
35
|
10K
|
8
|
|
ASX - By Stock
|
OIL |
Re:
Ann: Optiscan 2024 Roadshow Presentation
|
|
kosenar
|
18 |
5.4K |
1 |
01/07/24 |
01/07/24 |
ASX - By Stock
|
18
|
5.4K
|
1
|
|
ASX - By Stock
|
OIL |
Re:
Ann: Optiscan 2024 Roadshow Presentation
|
|
kosenar
|
18 |
5.4K |
3 |
01/07/24 |
01/07/24 |
ASX - By Stock
|
18
|
5.4K
|
3
|
|
ASX - By Stock
|
DLM |
Re:
Ann: Results of Meeting
|
|
kosenar
|
23 |
7.0K |
2 |
29/06/24 |
29/06/24 |
ASX - By Stock
|
23
|
7.0K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Clean insights and information easily found
|
|
kosenar
|
157 |
39K |
6 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
157
|
39K
|
6
|
|
ASX - By Stock
|
PER |
Re:
Clean insights and information easily found
|
|
kosenar
|
157 |
39K |
2 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
157
|
39K
|
2
|
|
ASX - By Stock
|
PER |
Re:
PER - Megathread
|
|
kosenar
|
366 |
121K |
11 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
366
|
121K
|
11
|
|
ASX - By Stock
|
PER |
Re:
PER - Megathread
|
|
kosenar
|
366 |
121K |
3 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
366
|
121K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Notification of upcoming expiry of Unlisted Options
|
|
kosenar
|
93 |
26K |
4 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
93
|
26K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
kosenar
|
163 |
56K |
5 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
163
|
56K
|
5
|
|
ASX - By Stock
|
PER |
Re:
6 months passed since first patient
|
|
kosenar
|
161 |
41K |
7 |
09/02/24 |
09/02/24 |
ASX - By Stock
|
161
|
41K
|
7
|
|
ASX - By Stock
|
PER |
Re:
6 months passed since first patient
|
|
kosenar
|
161 |
41K |
14 |
08/02/24 |
08/02/24 |
ASX - By Stock
|
161
|
41K
|
14
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
kosenar
|
3.5K |
1.0M |
5 |
26/12/23 |
26/12/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
5
|
|
ASX - By Stock
|
CTO |
Re:
Ann: Exploration Results
|
|
kosenar
|
9 |
4.4K |
5 |
12/12/23 |
12/12/23 |
ASX - By Stock
|
9
|
4.4K
|
5
|
|
ASX - By Stock
|
OIL |
Re:
Good signs ....
|
|
kosenar
|
687 |
241K |
0 |
12/12/23 |
12/12/23 |
ASX - By Stock
|
687
|
241K
|
0
|
|
ASX - By Stock
|
CTO |
Re:
Disappointed
|
|
kosenar
|
2 |
1.0K |
1 |
11/12/23 |
11/12/23 |
ASX - By Stock
|
2
|
1.0K
|
1
|
|
ASX - By Stock
|
CTO |
Re:
Ann: 2023 AGM Chairman's Address
|
|
kosenar
|
11 |
4.3K |
2 |
06/12/23 |
06/12/23 |
ASX - By Stock
|
11
|
4.3K
|
2
|
|
ASX - By Stock
|
OIL |
Re:
Ann: OIL Managing Director's Presentation & Chair's Address
|
|
kosenar
|
20 |
6.6K |
2 |
23/11/23 |
23/11/23 |
ASX - By Stock
|
20
|
6.6K
|
2
|
|
ASX - By Stock
|
ANZ |
Re:
Ann: ANZ 2023 Climate-related Financial Disclosures
|
|
kosenar
|
3 |
890 |
4 |
13/11/23 |
13/11/23 |
ASX - By Stock
|
3
|
890
|
4
|
|
ASX - By Stock
|
PER |
Re:
James Garner CEO upbeat on prospects.
|
|
kosenar
|
85 |
17K |
13 |
12/10/23 |
12/10/23 |
ASX - By Stock
|
85
|
17K
|
13
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
kosenar
|
3.5K |
1.0M |
8 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
8
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
kosenar
|
3.5K |
1.0M |
10 |
30/08/23 |
30/08/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
10
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
kosenar
|
3.5K |
1.0M |
9 |
29/08/23 |
29/08/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
9
|
|
ASX - By Stock
|
PER |
Re:
James Garner AKA JG
|
|
kosenar
|
190 |
51K |
4 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
190
|
51K
|
4
|
|
ASX - By Stock
|
KCN |
Re:
Chart
|
|
kosenar
|
1.0K |
363K |
0 |
03/08/23 |
03/08/23 |
ASX - By Stock
|
1.0K
|
363K
|
0
|
|
ASX - By Stock
|
MYL |
Re:
News
|
|
kosenar
|
14 |
7.1K |
0 |
31/07/23 |
31/07/23 |
ASX - By Stock
|
14
|
7.1K
|
0
|
|
ASX - By Stock
|
CTO |
Re:
Ann: Quarterly Activities Report and Appendix 5B
|
|
kosenar
|
11 |
5.3K |
4 |
24/07/23 |
24/07/23 |
ASX - By Stock
|
11
|
5.3K
|
4
|
|
ASX - By Stock
|
CTO |
Re:
Ann: Quarterly Activities Report and Appendix 5B
|
|
kosenar
|
21 |
9.1K |
5 |
05/07/23 |
05/07/23 |
ASX - By Stock
|
21
|
9.1K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive outcomes in DMD combination therapy animal study
|
|
kosenar
|
124 |
37K |
0 |
14/06/23 |
14/06/23 |
ASX - By Stock
|
124
|
37K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Change of Director's Interest Notices - NW and SP
|
|
kosenar
|
23 |
8.4K |
4 |
13/06/23 |
13/06/23 |
ASX - By Stock
|
23
|
8.4K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: First Patient Dosed in ATL1102 Phase IIb DMD Trial
|
|
kosenar
|
34 |
13K |
2 |
12/06/23 |
12/06/23 |
ASX - By Stock
|
34
|
13K
|
2
|
|
ASX - By Stock
|
CTO |
Re:
Ann: Half Year Report
|
|
kosenar
|
70 |
22K |
4 |
07/05/23 |
07/05/23 |
ASX - By Stock
|
70
|
22K
|
4
|
|
ASX - By Stock
|
CTO |
Re:
Ann: Half Year Report
|
|
kosenar
|
70 |
22K |
3 |
07/05/23 |
07/05/23 |
ASX - By Stock
|
70
|
22K
|
3
|
|
ASX - By Stock
|
PER |
Re:
anp chart
|
|
kosenar
|
1.0K |
313K |
7 |
04/05/23 |
04/05/23 |
ASX - By Stock
|
1.0K
|
313K
|
7
|
|
ASX - By Stock
|
PER |
Re:
anp chart
|
|
kosenar
|
1.0K |
313K |
1 |
29/04/23 |
29/04/23 |
ASX - By Stock
|
1.0K
|
313K
|
1
|
|
ASX - By Stock
|
PER |
Re:
anp chart
|
|
kosenar
|
1.0K |
313K |
3 |
29/04/23 |
29/04/23 |
ASX - By Stock
|
1.0K
|
313K
|
3
|
|
ASX - By Stock
|
OIL |
Re:
Ann: Change of Director's Interest Notice
|
|
kosenar
|
16 |
4.9K |
3 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
16
|
4.9K
|
3
|
|
ASX - By Stock
|
PER |
Re:
anp chart
|
|
kosenar
|
1.0K |
313K |
4 |
24/04/23 |
24/04/23 |
ASX - By Stock
|
1.0K
|
313K
|
4
|
|
ASX - By Stock
|
PER |
Albanese government pledges $50m for long Covid research as inquiry calls for action
|
|
kosenar
|
3 |
1.1K |
6 |
24/04/23 |
24/04/23 |
ASX - By Stock
|
3
|
1.1K
|
6
|
|
ASX - By Stock
|
CAY |
Re:
Cameroon government also has ongoing issues with Sundance Resources
|
|
kosenar
|
3 |
1.7K |
2 |
22/04/23 |
22/04/23 |
ASX - By Stock
|
3
|
1.7K
|
2
|
|
ASX - By Stock
|
CAY |
Cameroon government also has ongoing issues with Sundance Resources
|
|
kosenar
|
3 |
1.7K |
5 |
16/04/23 |
16/04/23 |
ASX - By Stock
|
3
|
1.7K
|
5
|
|
ASX - By Stock
|
OIL |
Re:
Ann: Optiscan Establishes US Commercial Operation in Minnesota
|
|
kosenar
|
21 |
8.4K |
5 |
12/04/23 |
12/04/23 |
ASX - By Stock
|
21
|
8.4K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Knock knock ! Is anyone there ?
|
|
kosenar
|
6 |
2.5K |
2 |
12/04/23 |
12/04/23 |
ASX - By Stock
|
6
|
2.5K
|
2
|
|
ASX - By Stock
|
CAY |
Re:
Still Waiting
|
|
kosenar
|
136 |
40K |
5 |
09/04/23 |
09/04/23 |
ASX - By Stock
|
136
|
40K
|
5
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
kosenar
|
3.5K |
1.0M |
17 |
02/04/23 |
02/04/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
17
|
|